Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 5, 2011 Dan Dzombak	This Company Could Go to Zero Lorillard faces 90% of its cigarette products being banned.
BusinessWeek June 24, 2010 Miles et al.	Altria vs. the FDA: More than a Mild Dispute Federal regulators want the tobacco company to hand over the research behind the selling of Marlboro Golds
The Motley Fool June 15, 2009 Colleen Paulson	Is This Sector Going Up in Smoke? The combination of increased taxes and FDA regulation of tobacco products certainly won't help the industry's future growth prospects in the United States.
The Motley Fool July 2, 2010 Colleen Paulson	Government Snuffs Marlboro's Lights FDA's moves to control cigarette labeling and packaging take a bite.
The Motley Fool August 2, 2011 Shubh Datta	A Smoky Outlook for Lorillard Q2 results were respectable, but the next quarter could be weaker for cigarette maker Lorillard.
The Motley Fool January 14, 2011 Colleen Paulson	Can Smoking Growth Continue in 2011? Tobacco stocks outperformed the S&P in 2010; will trend continue in 2011?
The Motley Fool May 26, 2009 Colleen Paulson	What's Your MO, Altria? Altria is actively supporting FDA regulation of cigarettes. Read on to see why.
The Motley Fool November 10, 2009 Colleen Paulson	Altria's Not Tobacco's Only Altruist Reynolds American may purchase a quit-smoking company.
The Motley Fool June 9, 2011 Neha Chamaria	How Big Tobacco's Trying to Regain Lost Ground in the U.S. Reynolds counters expanded smoking bans with its Camel Snus campaign.
The Motley Fool January 7, 2010 Colleen Paulson	Big Tobacco Is Back to Business Philip Morris USA touts "lower risk" smokeless tobacco.
The Motley Fool March 19, 2007 Brian Lawler	Is Dendreon Doomed? A pivotal FDA regulatory meeting approaches for the development-stage pharma. Investors, take note.
Reason Aug/Sep 2009 Jacob Sullum	Cigarette Gag: Smokes and speech In April a bill was passed that includes a provision barring manufacturers from making any statement directed to consumers through the media that would reasonably be expected to result in consumers believing that the product is regulated and endorsed by the FDA
Salon.com August 16, 2000 Cynthia Kuhn & Wilkie Wilson	The menthol myth I love those cool, fresh-tasting cigarettes but hear they are more cancerous than regular smokes. Is that true?
The Motley Fool August 1, 2007 Brian Lawler	Elan Gets a Vote of Confidence Elan receives some good news from an FDA advisory panel in the form of a recommendation to expand the use of Tysabri to treat Crohn's disease.
BusinessWeek September 13, 2004 Nanette Byrnes	Double Danger For Big Tobacco A U.S. Justice suit and a push for FDA oversight have cigarette makers gasping.
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
The Motley Fool April 11, 2008 Brian Lawler	Amgen's Unsurprising Delay The FDA extends its review of an Amgen drug candidate.
The Motley Fool July 18, 2011 Jim Royal	Big Tobacco Faces Another Huge Headwind More packaging changes could dent these players' profits.
The Motley Fool October 19, 2010 Brian Orelli	Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency.
The Motley Fool November 29, 2007 Brian Lawler	Another Chapter in Glaxo's Relenza Saga An FDA advisory panel suggested that the Relenza label should be strengthened to include the possibility of abnormal behavior and hallucinations in those who take it.
Bio-IT World April 15, 2003 Janet Woodcock	FDA Director Explains the Changes The head of the Center for Drug Evaluation and Research discusses why the FDA is now kinder and gentler about Part 11 compliance.
AskMen.com	Obama To Sign Anti-Smoking Bill President Barack Obama is set to sign into law an anti-smoking bill that will give the Food and Drug Administration unprecedented authority to regulate tobacco.
Chemistry World November 4, 2008 Rebecca Trager	FDA criticised by its own experts over bisphenol A The US Food and Drug Administration (FDA)'s recent conclusion that controversial chemical bisphenol A (BPA) is safe at current levels is flawed, the agency's own Science Board has warned.
IndustryWeek October 19, 2011	FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies?
The Motley Fool August 21, 2008 Brian Orelli	Johnson & Johnson Gets Rejected The FDA rejects Johnson & Johnson's bid to expand the label of its antibiotic.
Bio-IT World April 15, 2003 Heller & Philbin	Part 11: The FDA's New View The FDA now has a softer perspective on enforcement, but companies will still have to watch their step.
The Motley Fool December 6, 2010 Brian Orelli	3-Month Delay? No Problem! Investors shrug off HGS' Benlysta delay. The Food and Drug Administration's delaying its decision on whether to approve Human Genome Sciences and GlaxoSmithKline's Benlysta shouldn't come as much of a surprise.
The Motley Fool May 13, 2011 Brian Orelli	FDA Advisory Panel Positive! Shares Punished. Despite the positive recommendation, investors aren't convinced BioMimetic's Augment will be approved.
The Motley Fool March 17, 2008 Brian Lawler	The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared.
The Motley Fool February 4, 2009 Brian Orelli	Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval.
The Motley Fool August 6, 2009 Colleen Paulson	The Military's Fightin' the (Marlboro) Man The Pentagon has recently completed a study arguing that tobacco use should be banned in the military and sales prohibited on government-owned property. It's clear that Altria, Reynolds American, and Lorillard have their work cut out for them.
The Motley Fool May 28, 2011 Frank Vinluan	Philip Morris Buys Smokeless Nicotine Technology From Duke Researcher The new system could deliver a quicker nicotine hit with fewer chemicals.
The Motley Fool September 11, 2009 Colleen Paulson	Altria Blazes On The tobacco giant sets itself apart with new product plans.
The Motley Fool November 22, 2011 Austin Smith	Big Tobacco Turns the Tables In an industry rife with lawsuits, Philip Morris tries on the other shoe.
The Motley Fool October 19, 2010 Brian Orelli	When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday.
The Motley Fool August 12, 2008 Brian Lawler	The FDA Stands Up Cardiome What does the approvable letter mean for Cardiome and other drug developers?
The Motley Fool October 11, 2010 Brian Orelli	What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third...
The Motley Fool February 28, 2008 Brian Lawler	FDA's Mixed Signals for Theravance The FDA gives Theravance frustrating double messages about a lead drug.
The Motley Fool February 27, 2009 Brian Orelli	Get a Life, Congress! A Congressional investigation into whether the FDA was right to pull a doctor off of the advisory panel for Eli Lilly's blood thinner prasugrel illustrates why Congress needs to keep its nose out of scientific discussions.
AskMen.com	WHO: Get Graphic With Smokers Cigarette packages should include images of sickness and suffering caused by tobacco, along with written warnings, the World Health Organization said.
Food Engineering June 4, 2007	Congress to beef up inspection activities With one food recall after another making headlines, Congress appears intent on beefing up federal government food inspection activities.
AskMen.com	China: No Free Cigs For Party China's corruption watchdog will clamp down on government officials who use public money to buy expensive cigarettes.
The Motley Fool January 14, 2008 Brian Lawler	Score One for Dendreon and Disclosure A prestigious journal supports Dendreon's potential prostate cancer treatment, and makes a compelling case for more FDA disclosure.
The Motley Fool December 31, 2007 Brian Lawler	Lower Expectations for Theravance The FDA decides to debate Theravance's lead drug, Telavancin, leading to a drop in share price.
Bio-IT World April 15, 2003 Barbara Depompa Reimers	Easing the Pain of Part 11 Costs for complying with FDA electronic records regulations will cost millions of dollars per company by 2006. Risk-based processes can lighten the load.
Pharmaceutical Executive December 1, 2011 Jill Wechsler	FDA Gets a New Look Agency expansion and globalization promote innovation, collaboration, and organizational changes
The Motley Fool December 19, 2011 Dan Caplinger	Star Scientific Had a Great 2011 With Star Scientific looking to emphasize dissolvable tobacco and developing a process to cure tobacco in a non-carcinogenic way, investors could see the stock as the best way to play the industry.
The Motley Fool December 8, 2010 Brian Orelli	Up 100% With Room to Fly Orexigen gets a positive FDA panel nod.
HBS Working Knowledge April 23, 2014 Michael Blanding	Are Electronic Cigarettes a Public Good or Health Hazard? A new case study by John Quelch charts the growing popularity of electronic cigarettes and how tobacco companies and regulators are responding.
The Motley Fool August 2, 2010 Anand Chokkavelu	Why We're Buying Altria Due to smoking bans and health consciousness, cigarette usage in the U.S. is on the way down at a rate of 3%-4% a year.